Automate Your Wheel Strategy on GSK
With Tiblio's Option Bot, you can configure your own wheel strategy including GSK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GSK
- Rev/Share 15.9474
- Book/Share 10.5137
- PB 3.3668
- Debt/Equity 1.0992
- CurrentRatio 0.8363
- ROIC 0.1128
- MktCap 73782240299.6166
- FreeCF/Share 2.9515
- PFCF 12.3937
- PE 13.3223
- Debt/Assets 0.2894
- DivYield 0.0343
- ROE 0.2972
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 4
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | GSK | BofA Securities | Underperform | Neutral | -- | -- | Nov. 25, 2025 |
| Downgrade | GSK | Berenberg | Buy | Hold | -- | -- | June 3, 2025 |
| Initiation | GSK | Exane BNP Paribas | -- | Neutral | -- | $35.25 | April 15, 2025 |
| Initiation | GSK | Morgan Stanley | -- | Equal Weight | -- | -- | Feb. 12, 2025 |
News
Drug Sector on a High as 9 Drugmakers Strike Drug Pricing Deals
Published: December 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Amgen and eight other pharma giants struck deals with the Trump administration to cut U.S. drug prices while gaining tariff relief and manufacturing incentives.
Read More
GSK is next to agree drug pricing deal with US government
Published: December 22, 2025 by: Proactive Investors
Sentiment: Neutral
GSK PLC (LSE:GSK, NYSE:GSK) has become the latest big pharma company to fall into line with the US government's "most favoured nation" drug pricing regime, in exchange for an exemption from tariffs. The FTSE 100 group said the voluntary agreement with the White House implements all four policy actions requested by President Trump earlier this year.
Read More
Samsung Biologics to buy U.S. drug production facility from GSK for $280 mln
Published: December 21, 2025 by: Reuters
Sentiment: Positive
South Korea's Samsung Biologics said on Monday its U.S. unit is buying a U.S. drug production facility from GSK for $280 million.
Read More
Samsung Biologics Expands U.S. Manufacturing Capabilities with Strategic Acquisition of Human Genome Sciences from GSK
Published: December 21, 2025 by: PRNewsWire
Sentiment: Neutral
Secures the company's first U.S.-based manufacturing site, strengthening and diversifying its global supply network Additional investments planned to expand the site's capacity (currently at 60,000 liters of drug substance) and capabilities to support growing manufacturing programs Underscores Samsung Biologics' long-term dedication to the U.S. biopharmaceutical industry and supply chain INCHEON, South Korea, ROCKVILLE, Md. and LONDON , Dec. 21, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced that its wholly owned U.S. subsidiary, Samsung Biologics America, has entered into a definitive agreement to acquire 100% of Human Genome Sciences from GSK …
Read More
Here's Why GSK (GSK) is a Strong Growth Stock
Published: December 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
GSK's Exdensur Gets FDA Nod for Severe Asthma Treatment
Published: December 17, 2025 by: Zacks Investment Research
Sentiment: Positive
GSK secures FDA approval for Exdensur, the first twice-yearly biologic for treating severe asthma with an eosinophilic phenotype.
Read More
UK approves GSK's twice-yearly asthma drug
Published: December 15, 2025 by: Reuters
Sentiment: Positive
UK's health regulator on Monday approved GSK's twice-yearly drug for use as an add-on treatment for asthma in patients aged 12 and older, as well as for a chronic inflammatory sinus condition in adults.
Read More
GSK's Nucala for COPD and Depemokimab for Asthma Get CHMP Nod in EU
Published: December 15, 2025 by: Zacks Investment Research
Sentiment: Positive
GSK gets CHMP backing for Nucala in COPD and depemokimab in asthma, setting up possible Europe approvals in 2026 for IL-5 therapies.
Read More
GSK Gets FDA Nod for Blujepa in Uncomplicated Urogenital Gonorrhea
Published: December 12, 2025 by: Zacks Investment Research
Sentiment: Positive
GSK wins FDA approval for Blujepa, a new oral antibiotic treatment option for uncomplicated urogenital gonorrhea.
Read More
GSK gets EU regulator backing for expanded use of RSV vaccine
Published: December 12, 2025 by: Reuters
Sentiment: Positive
GSK said on Friday a panel of the European Medicines Agency had backed the use of its respiratory syncytial virus (RSV) vaccine, Arexvy, for all adults above the age of 18, paving the way for broader use.
Read More
European health regulator recommends approval for GSK's twice yearly asthma drug
Published: December 12, 2025 by: Reuters
Sentiment: Positive
The European Medicines Agency has recommended the approval of GSK's add-on drug to treat asthma and a chronic inflammatory sinus condition, the company said on Friday.
Read More
GSK's Risvutatug Rezetecan Gets FDA's Orphan Drug Tag in Lung Cancer
Published: December 11, 2025 by: Zacks Investment Research
Sentiment: Positive
GSK gains FDA Orphan Drug Designation for risvutatug rezetecan, adding momentum to its fast-advancing solid-tumor pipeline.
Read More
GSK Stock Up Almost 19% in 3 Months: Should You Buy, Hold or Sell?
Published: December 11, 2025 by: Zacks Investment Research
Sentiment: Positive
GSK's stock surge rides on strong Q3 results and raised guidance, as Specialty Medicines momentum offsets U.S. vaccine softness.
Read More
Here's Why GSK (GSK) is a Strong Value Stock
Published: December 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Here's Why GSK (GSK) is a Strong Growth Stock
Published: December 03, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Why GSK (GSK) is a Top Value Stock for the Long-Term
Published: November 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
AnaptysBio shares tumble after legal fight with GSK over cancer drug license
Published: November 21, 2025 by: Reuters
Sentiment: Negative
Shares of AnaptysBio fell 14% in premarket trading on Friday after the U.S. drug developer and Tesaro, a unit of Britain's GSK , filed lawsuits against each other, with both claiming a breach in a partnership deal for a cancer drug.
Read More
GSK plc (GSK) Presents at Jefferies London Healthcare Conference 2025 Transcript
Published: November 19, 2025 by: Seeking Alpha
Sentiment: Neutral
GSK plc ( GSK ) Jefferies London Healthcare Conference 2025 November 19, 2025 4:30 AM EST Company Participants Tony Wood - Chief Scientific Officer and Head of R&D Conference Call Participants Michael Leuchten - Jefferies LLC, Research Division Presentation Michael Leuchten Jefferies LLC, Research Division Good morning, everybody. My name is Michael Leuchten, covering analyst on Glaxo here at Jefferies.
Read More
GSK (GSK) is a Top-Ranked Momentum Stock: Should You Buy?
Published: November 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Why GSK (GSK) is a Top Growth Stock for the Long-Term
Published: November 13, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
3 Dividend Stocks for November 2025
Published: November 04, 2025 by: Morningstar
Sentiment: Neutral
This month's trio includes two ADRs.
Read More
GSK's shares stuck in the middle lane
Published: November 04, 2025 by: Proactive Investors
Sentiment: Neutral
GSK PLC's (LSE:GSK, NYSE:GSK) latest quarter looked strong enough on pape, but the share price barely moved. The drugmaker has spent much of the past decade trapped between £15 and £18, and Deutsche Bank thinks that pattern is unlikely to change soon.
Read More
Aviva, GSK, Rolls and bitcoin miners: UK investors most trades shares in October
Published: October 31, 2025 by: Proactive Investors
Sentiment: Neutral
Retail investors on two UK platforms poured into a mix of large financials, big tech and crypto-related names and resource security plays in October, according to the latest trading data. On AJ Bell, which offers trading in all UK stocks, plus most of those available in New York and major European exchanges, investor activity showed a tilt toward income and blue-chip names.
Read More
GSK's Q3 Earnings & Sales Beat Estimates, Stock Up on Raised '25 View
Published: October 29, 2025 by: Zacks Investment Research
Sentiment: Positive
GSK's Q3 earnings and revenue beat expectations, powered by HIV and oncology growth, prompting the company to lift its 2025 outlook.
Read More
GSK plc (GSK) Q3 2025 Earnings Call Transcript
Published: October 29, 2025 by: Seeking Alpha
Sentiment: Neutral
GSK plc ( GSK ) Q3 2025 Earnings Call October 29, 2025 8:00 AM EDT Company Participants Emma Walmsley - CEO & Director Luke Miels - Chief Commercial Officer Deborah Waterhouse - CEO of ViiV Healthcare & President of Global Health Julie Brown - CFO & Executive Director Tony Wood - Chief Scientific Officer and Head of R&D Conference Call Participants Peter Verdult - BNP Paribas Exane, Research Division Matthew Weston - UBS Investment Bank, Research Division Michael Leuchten - Jefferies LLC, Research Division Luisa Hector - Joh. Berenberg, Gossler & Co. KG, Research Division Sachin Jain - BofA Securities, …
Read More
GSK (GSK) Q3 Earnings and Revenues Beat Estimates
Published: October 29, 2025 by: Zacks Investment Research
Sentiment: Positive
GSK (GSK) came out with quarterly earnings of $1.48 per share, beating the Zacks Consensus Estimate of $1.26 per share. This compares to earnings of $1.27 per share a year ago.
Read More
GSK lifts profit outlook after strong quarter and upbeat broker reaction
Published: October 29, 2025 by: Proactive Investors
Sentiment: Positive
GSK PLC (LSE:GSK, NYSE:GSK) shares rose 4% to 1,707p after the pharmaceutical group raised its full-year guidance and delivered quarterly results that topped forecasts across almost every metric. The upbeat figures, helped by a strong performance in Specialty Medicines and vaccines, also prompted positive analyst commentary, with Jefferies reaffirming its 'buy' rating and setting a price target of 2,000p.
Read More
GSK Raises Guidance After Sales, Earnings Growth
Published: October 29, 2025 by: WSJ
Sentiment: Positive
The drugmaker now expects 2025 sales growth between 6% to 7% when excluding currency movements, up from a 3% to 5% range.
Read More
GSK hikes outlook as sales and earning grow faster than expected
Published: October 29, 2025 by: Proactive Investors
Sentiment: Positive
GSK PLC (LSE:GSK, NYSE:GSK) raised its outlook for the full year after beating expectations with third-quarter revenues and earnings per share. Group revenues for the FTSE 100 drugmaker came in at £8.55 billion for the quarter to the end of September, up 7% on the same period last year and topping the average City forecast of £8.28 billion.
Read More
GSK raises 2025 sales forecast after strong growth in specialty medicines
Published: October 29, 2025 by: Reuters
Sentiment: Positive
GSK raised its 2025 sales expectations on Wednesday after third-quarter results beat expectations, driven by double-digit growth in its specialty medicines, including HIV and oncology.
Read More
About GSK plc (GSK)
- IPO Date 1980-03-28
- Website https://www.gsk.com
- Industry Drug Manufacturers - General
- CEO Emma Natasha Walmsley
- Employees 68629